Abstract
Fibroblast growth factor receptor 4 (FGFR4), a member of the fibroblast growth receptor family, was recently reported to be more abundantly expressed in malignant than benign prostate cells. A single nucleotide polymorphism at position 388 of the FGFR4 amino-acid sequence results in the substitution of glycine (Gly) with arginine (Arg) and higher frequency of the ArgArg genotype was previously found in prostate cancer patients. DNA was extracted from the blood drawn from 399 prostate cancer patients, 150 BPH patients and 294 healthy community controls. Polymerase chain reaction was carried out and single nucleotide polymorphisms of FGFR4 were identified by restriction enzyme digestion. No overall association is detectable between the Arg allele and increased prostate cancer risk. Subgroup analysis shows a higher incidence of the heterozygous ArgGly genotype in cancer cases than in the combined group of BPH and controls (P<0.05); this difference is statistically significant between cancer and BPH patients but not between cancer cases and community controls. The single nucleotide polymorphism Gly388Arg in FGFR4 is not associated with increased risk of prostate cancer in Scottish men. This observation is in contrast with results from two previous studies conducted in the USA and Japan.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
NHS Scotland Information Services Division. Cancer in Scotland. 2008.
Sahadevan K, Darby S, Leung HY, Mathers ME, Robson CN, Gnanapragasam VJ . Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. J Pathol 2007; 213: 82–90.
Wilkie AO, Morriss-Kay GM, Jones EY, Heath JK . Functions of fibroblast growth factors and their receptors. Curr Biol 1995; 5: 500–507.
Eswarakumar VP, Lax I, Schlessinger J . Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev 2005; 16: 139–149.
Wang J, Stockton DW, Ittmann M . The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. Clin Cancer Res 2004; 10 (18 Part 1): 6169–6178.
Ma Z, Tsuchiya N, Yuasa T, Inoue T, Kumazawa T, Narita S et al. Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population. Int J Cancer 2008; 123: 2574–2579.
Binnie MC, Alexander FE, Heald C, Habib FK . Polymorphic forms of prostate specific antigen and their interaction with androgen receptor trinucleotide repeats in prostate cancer. Prostate 2005; 63: 309–315.
Bange J, Prechtl D, Cheburkin Y, Specht K, Harbeck N, Schmitt M et al. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 2002; 62: 840–847.
Bland JM, Altman DG . Statistics notes. The odds ratio. BMJ 2000; 320: 1468.
da Costa Andrade VC, Parise Jr O, Hors CP, de Melo Martins PC, Silva AP, Garicochea B . The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma. Exp Mol Pathol 2007; 82: 53–57.
Hsing AW, Tsao L, Devesa SS . International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 2000; 85: 60–67.
Acknowledgements
This study was supported by a grant from Cancer Research UK. We thank Margaret Binnie for her technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ho, C., Anwar, S., Nanda, J. et al. FGFR4 Gly388Arg polymorphism and prostate cancer risk in Scottish men. Prostate Cancer Prostatic Dis 13, 94–96 (2010). https://doi.org/10.1038/pcan.2009.49
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2009.49
Keywords
This article is cited by
-
Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer
Scientific Reports (2021)
-
FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer
Acta Pharmacologica Sinica (2013)
-
Analysis of prostate cancer association with four single-nucleotide polymorphisms from genome-wide studies and serum phyto-estrogen concentrations
Prostate Cancer and Prostatic Diseases (2012)